FOLD News and Press, Amicus Therapeutics Inc. From 04/26/23

European Commission Approval of Opfolda and Commercial Launch of Pombiliti ® + Opfolda ® Anticipated in 3Q 2023 Upon Approval, Pombiliti + Opfolda will be the First Two-Component Therapy in the European Union for the Treatment of Adu...

2023-04-21 17:30:06 ET Gold fell sharply Friday and posted its worst week since February, as hawkish remarks by Federal Reserve officials seemed to raise the likelihood for at least one more interest rate hike. Cleveland Fed President Loretta Mester was the latest to state her suppo...

2023-04-12 16:30:23 ET Gold futures closed Wednesday at their highest in nearly a week, with the dollar declining as signs of cooling inflation added to hopes for a pause in U.S. rate increases. The Consumer Price Index rose by a less than expected 0.1% in March after climbing 0.4% ...

2023-03-27 07:47:09 ET Amicus Therapeutics ( NASDAQ: FOLD ) has received approval from the European Commission for its Pombiliti enzyme replacement therapy. The Commission approved Pombiliti as a long-term enzyme replacement therapy, in combination with miglustat, for adul...

Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer Component of AT-GAA, On-Track for 2Q 2023 PHILADELPHIA, March 27, 2023 (GLOBE NEW...

2023-03-08 13:57:48 ET Summary Amicus ended FY’22 with a growing topline and reassuring outlook from the management. The company seems well-prepared for pre-approval inspection and also seems optimistic about regulatory approval of their AT-GAA this year. The success of...

Amicus Therapeutics. (FOLD) Q4 2022 Earnings Conference Call March 01, 2023, 08:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President, Chief Executive Officer Sébastien Martel - Chief Business Officer J...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Amicus Therapeutics, Inc. 2022 Q4 - Results - Earnings Call Presentation

Amicus Therapeutics press release ( NASDAQ: FOLD ): FY GAAP EPS of -$0.82 misses by $0.05 . Revenue of $329.23M (+7.8% Y/Y) beats by $0.33M . Cash, cash equivalents, and marketable securities totaled $293.6 million at December 31, 2022, compared to $482.5 million at De...

2022 Revenue Growth of 16% at CER to $329M Projecting Galafold Revenue Growth in 2023 of 12-17% at CER U.S. FDA Pre-approval Inspection for AT-GAA Now Scheduled; Approval expected in 3Q 2023 EU and U.K. AT-GAA Regulatory Reviews On-Track; Approvals expected i...